Nuclear Medicine Applications for Neuroendocrine Tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-11

AUTHORS

J.F. Chatal, M.F. Le Bodic, F. Kraeber-Bodéré, C. Rousseau, I. Resche

ABSTRACT

Sensitive, specific radiopharmaceuticals are available for scintigraphic diagnosis and internal radiotherapy of neuroendocrine tumors. 123I-MIBG (metaiodobenzylguanidine) scintigraphy is the examination of choice for visualizing tumor sites of pheochromocytoma. In the event of malignant pheochromocytoma or carcinoid tumor, this examination allows assessment of the presence or absence of tumor uptake and can guide radiotherapy with 131I-MIBG. The peptides secreted by neuroendocrine tumors can be radiolabeled for targeting of their specific receptors. Scintigraphy using a 111In-labeled somatostatin analog (octreotide) is the examination of choice for diagnosis of the spread of gastroenteropancreatic and carcinoid tumors, as it is more sensitive than morphologic imaging techniques. It can also guide radiotherapy performed with the same pharmaceutical vector. These same two agents (MIBG and octreotide) can be used therapeutically by replacing 123I with 131I and 111In by 90Y. A transient palliative effect is obtained for a variable number of tumors (most often large ones) that take up the radiopharmaceutic agent well. There is general consensus that, for relatively radioresistant solid tumors, this type of radiotherapy is efficient only in the event of small tumor targets (a few millimeters in diameter) whose uptake is maximal, allowing more homogeneous distribution than that achieved with large tumors. Thus for optimal control of the disease it is recommended first to use scintigraphic imaging to confirm that the tumor takes up the radiopharmaceutical agent in question (123I-MIBG or 111In-octreotide) and then reduce the tumor burden surgically before injecting high therapeutic activity (possibly with reinjection of peripheral stem cells). This treatment can be repeated three times every 3 months before evaluating the response. In these conditions, internal radiotherapy can be beneficial or even determinant for controlling disease progression. More... »

PAGES

1285-1289

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s002680010213

DOI

http://dx.doi.org/10.1007/s002680010213

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016994149

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11038195


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "3-Iodobenzylguanidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoid Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuroendocrine Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nuclear Medicine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Octreotide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pheochromocytoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radioimmunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radionuclide Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sensitivity and Specificity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thyroid Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service de M\u00e9decine Nucl\u00e9aire, Centre R\u00e9gional de Lutte contre le Cancer Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Service de M\u00e9decine Nucl\u00e9aire, Centre R\u00e9gional de Lutte contre le Cancer Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chatal", 
        "givenName": "J.F.", 
        "id": "sg:person.0623457423.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623457423.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service d'Anatomie Pathologique, C.H.U., Nantes-Saint Herblain, France, FR", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Service d'Anatomie Pathologique, C.H.U., Nantes-Saint Herblain, France, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Le Bodic", 
        "givenName": "M.F.", 
        "id": "sg:person.077074621.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.077074621.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de M\u00e9decine Nucl\u00e9aire, Centre R\u00e9gional de Lutte contre le Cancer Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Service de M\u00e9decine Nucl\u00e9aire, Centre R\u00e9gional de Lutte contre le Cancer Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kraeber-Bod\u00e9r\u00e9", 
        "givenName": "F.", 
        "id": "sg:person.0653324404.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de M\u00e9decine Nucl\u00e9aire, Centre R\u00e9gional de Lutte contre le Cancer Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Service de M\u00e9decine Nucl\u00e9aire, Centre R\u00e9gional de Lutte contre le Cancer Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rousseau", 
        "givenName": "C.", 
        "id": "sg:person.01240530667.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service de M\u00e9decine Nucl\u00e9aire, Centre R\u00e9gional de Lutte contre le Cancer Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Service de M\u00e9decine Nucl\u00e9aire, Centre R\u00e9gional de Lutte contre le Cancer Ren\u00e9 Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Resche", 
        "givenName": "I.", 
        "id": "sg:person.0776514743.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776514743.28"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00199342", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003722545", 
          "https://doi.org/10.1007/bf00199342"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590050268", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026262896", 
          "https://doi.org/10.1007/s002590050268"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-11", 
    "datePublishedReg": "2000-11-01", 
    "description": "Sensitive, specific radiopharmaceuticals are available for scintigraphic diagnosis and internal radiotherapy of neuroendocrine tumors. 123I-MIBG (metaiodobenzylguanidine) scintigraphy is the examination of choice for visualizing tumor sites of pheochromocytoma. In the event of malignant pheochromocytoma or carcinoid tumor, this examination allows assessment of the presence or absence of tumor uptake and can guide radiotherapy with 131I-MIBG. The peptides secreted by neuroendocrine tumors can be radiolabeled for targeting of their specific receptors. Scintigraphy using a 111In-labeled somatostatin analog (octreotide) is the examination of choice for diagnosis of the spread of gastroenteropancreatic and carcinoid tumors, as it is more sensitive than morphologic imaging techniques. It can also guide radiotherapy performed with the same pharmaceutical vector. These same two agents (MIBG and octreotide) can be used therapeutically by replacing 123I with 131I and 111In by 90Y. A transient palliative effect is obtained for a variable number of tumors (most often large ones) that take up the radiopharmaceutic agent well. There is general consensus that, for relatively radioresistant solid tumors, this type of radiotherapy is efficient only in the event of small tumor targets (a few millimeters in diameter) whose uptake is maximal, allowing more homogeneous distribution than that achieved with large tumors. Thus for optimal control of the disease it is recommended first to use scintigraphic imaging to confirm that the tumor takes up the radiopharmaceutical agent in question (123I-MIBG or 111In-octreotide) and then reduce the tumor burden surgically before injecting high therapeutic activity (possibly with reinjection of peripheral stem cells). This treatment can be repeated three times every 3 months before evaluating the response. In these conditions, internal radiotherapy can be beneficial or even determinant for controlling disease progression.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s002680010213", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1086446", 
        "issn": [
          "0364-2313", 
          "1432-2323"
        ], 
        "name": "World Journal of Surgery", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "examination of choice", 
      "neuroendocrine tumors", 
      "carcinoid tumors", 
      "internal radiotherapy", 
      "transient palliative effect", 
      "type of radiotherapy", 
      "morphologic imaging techniques", 
      "small tumor targets", 
      "high therapeutic activity", 
      "malignant pheochromocytoma", 
      "tumor burden", 
      "somatostatin analogues", 
      "large tumors", 
      "disease progression", 
      "palliative effect", 
      "scintigraphic diagnosis", 
      "tumor targets", 
      "scintigraphic imaging", 
      "tumor uptake", 
      "solid tumors", 
      "radioresistant solid tumors", 
      "radiopharmaceutical agent", 
      "radiotherapy", 
      "tumor site", 
      "tumors", 
      "therapeutic activity", 
      "specific receptors", 
      "specific radiopharmaceuticals", 
      "scintigraphy", 
      "pheochromocytoma", 
      "diagnosis", 
      "examination", 
      "imaging techniques", 
      "agents", 
      "general consensus", 
      "disease", 
      "uptake", 
      "progression", 
      "months", 
      "receptors", 
      "burden", 
      "treatment", 
      "radiopharmaceuticals", 
      "variable number", 
      "events", 
      "imaging", 
      "peptides", 
      "response", 
      "assessment", 
      "nuclear medicine applications", 
      "target", 
      "absence", 
      "consensus", 
      "medicine applications", 
      "control", 
      "activity", 
      "spread", 
      "choice", 
      "effect", 
      "presence", 
      "analogues", 
      "sites", 
      "number", 
      "types", 
      "time", 
      "questions", 
      "conditions", 
      "technique", 
      "vector", 
      "distribution", 
      "homogeneous distribution", 
      "applications", 
      "optimal control"
    ], 
    "name": "Nuclear Medicine Applications for Neuroendocrine Tumors", 
    "pagination": "1285-1289", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016994149"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s002680010213"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11038195"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s002680010213", 
      "https://app.dimensions.ai/details/publication/pub.1016994149"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_336.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s002680010213"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002680010213'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002680010213'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002680010213'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002680010213'


 

This table displays all metadata directly associated to this object as RDF triples.

232 TRIPLES      21 PREDICATES      116 URIs      106 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s002680010213 schema:about N02bcf846bbb8423396d54d188bfe4bf6
2 N205eeb0ab4634faf86b8bb6ea4782bb7
3 N57e77f92de764ddfad67b7aae3e61b3b
4 N625fa8c00de64c4f805fdedbcc0cacf3
5 N8ec035d8c9c2482a866d2e2e2bd5440f
6 N9f22476d43354375be5b7533730b8e1c
7 Na23c034f124d4f2fb236ebe09d949859
8 Na4cf0f20e2054665a7bcca3e024ad054
9 Naf47c87082a34ffeb0a4d766581a60a7
10 Nb85dd8b023c64ead8ee2e0f120a8fd88
11 Nc65612329a3c4e9ab1737cfc20ca8633
12 Nce3bf2d8b8a34f3eaf7515508c4dc561
13 Ndea4ad495f724b2f8cf523db85ae0152
14 Neeba3d4d6a544d1096354956b1286373
15 Nfdc909059c214fd2af03ea0931393d5e
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N5eeb9dcab2154dc686231838058b0a55
19 schema:citation sg:pub.10.1007/bf00199342
20 sg:pub.10.1007/s002590050268
21 schema:datePublished 2000-11
22 schema:datePublishedReg 2000-11-01
23 schema:description Sensitive, specific radiopharmaceuticals are available for scintigraphic diagnosis and internal radiotherapy of neuroendocrine tumors. 123I-MIBG (metaiodobenzylguanidine) scintigraphy is the examination of choice for visualizing tumor sites of pheochromocytoma. In the event of malignant pheochromocytoma or carcinoid tumor, this examination allows assessment of the presence or absence of tumor uptake and can guide radiotherapy with 131I-MIBG. The peptides secreted by neuroendocrine tumors can be radiolabeled for targeting of their specific receptors. Scintigraphy using a 111In-labeled somatostatin analog (octreotide) is the examination of choice for diagnosis of the spread of gastroenteropancreatic and carcinoid tumors, as it is more sensitive than morphologic imaging techniques. It can also guide radiotherapy performed with the same pharmaceutical vector. These same two agents (MIBG and octreotide) can be used therapeutically by replacing 123I with 131I and 111In by 90Y. A transient palliative effect is obtained for a variable number of tumors (most often large ones) that take up the radiopharmaceutic agent well. There is general consensus that, for relatively radioresistant solid tumors, this type of radiotherapy is efficient only in the event of small tumor targets (a few millimeters in diameter) whose uptake is maximal, allowing more homogeneous distribution than that achieved with large tumors. Thus for optimal control of the disease it is recommended first to use scintigraphic imaging to confirm that the tumor takes up the radiopharmaceutical agent in question (123I-MIBG or 111In-octreotide) and then reduce the tumor burden surgically before injecting high therapeutic activity (possibly with reinjection of peripheral stem cells). This treatment can be repeated three times every 3 months before evaluating the response. In these conditions, internal radiotherapy can be beneficial or even determinant for controlling disease progression.
24 schema:genre article
25 schema:isAccessibleForFree false
26 schema:isPartOf N8fdb76035c74492b9cd431bda18eb2da
27 Nabc814c9fada44f9929a5c52f5ab91e9
28 sg:journal.1086446
29 schema:keywords absence
30 activity
31 agents
32 analogues
33 applications
34 assessment
35 burden
36 carcinoid tumors
37 choice
38 conditions
39 consensus
40 control
41 diagnosis
42 disease
43 disease progression
44 distribution
45 effect
46 events
47 examination
48 examination of choice
49 general consensus
50 high therapeutic activity
51 homogeneous distribution
52 imaging
53 imaging techniques
54 internal radiotherapy
55 large tumors
56 malignant pheochromocytoma
57 medicine applications
58 months
59 morphologic imaging techniques
60 neuroendocrine tumors
61 nuclear medicine applications
62 number
63 optimal control
64 palliative effect
65 peptides
66 pheochromocytoma
67 presence
68 progression
69 questions
70 radiopharmaceutical agent
71 radiopharmaceuticals
72 radioresistant solid tumors
73 radiotherapy
74 receptors
75 response
76 scintigraphic diagnosis
77 scintigraphic imaging
78 scintigraphy
79 sites
80 small tumor targets
81 solid tumors
82 somatostatin analogues
83 specific radiopharmaceuticals
84 specific receptors
85 spread
86 target
87 technique
88 therapeutic activity
89 time
90 transient palliative effect
91 treatment
92 tumor burden
93 tumor site
94 tumor targets
95 tumor uptake
96 tumors
97 type of radiotherapy
98 types
99 uptake
100 variable number
101 vector
102 schema:name Nuclear Medicine Applications for Neuroendocrine Tumors
103 schema:pagination 1285-1289
104 schema:productId N9586f7e5db8b4e7e98ffcb01746515aa
105 Na97af9be5a994c458f8bd237ae4b5ffa
106 Nb2f072047f114f0fa67fcd28a469cdef
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016994149
108 https://doi.org/10.1007/s002680010213
109 schema:sdDatePublished 2022-12-01T06:22
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N7e7a19cb8d3947e5bc67e4c53340b55e
112 schema:url https://doi.org/10.1007/s002680010213
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N02bcf846bbb8423396d54d188bfe4bf6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Prognosis
118 rdf:type schema:DefinedTerm
119 N205eeb0ab4634faf86b8bb6ea4782bb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Male
121 rdf:type schema:DefinedTerm
122 N365e5fc4962c472990d506303c309e85 rdf:first sg:person.0776514743.28
123 rdf:rest rdf:nil
124 N57e77f92de764ddfad67b7aae3e61b3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Humans
126 rdf:type schema:DefinedTerm
127 N5eeb9dcab2154dc686231838058b0a55 rdf:first sg:person.0623457423.87
128 rdf:rest Na58ce306a8734e5ca692457efaa1f5f9
129 N625fa8c00de64c4f805fdedbcc0cacf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Nuclear Medicine
131 rdf:type schema:DefinedTerm
132 N7e7a19cb8d3947e5bc67e4c53340b55e schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 N86401cd8bb9848d2a166512d83036da1 rdf:first sg:person.01240530667.47
135 rdf:rest N365e5fc4962c472990d506303c309e85
136 N8ec035d8c9c2482a866d2e2e2bd5440f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Sensitivity and Specificity
138 rdf:type schema:DefinedTerm
139 N8fdb76035c74492b9cd431bda18eb2da schema:volumeNumber 24
140 rdf:type schema:PublicationVolume
141 N9586f7e5db8b4e7e98ffcb01746515aa schema:name pubmed_id
142 schema:value 11038195
143 rdf:type schema:PropertyValue
144 N9f22476d43354375be5b7533730b8e1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Octreotide
146 rdf:type schema:DefinedTerm
147 Na23c034f124d4f2fb236ebe09d949859 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Radioimmunotherapy
149 rdf:type schema:DefinedTerm
150 Na4cf0f20e2054665a7bcca3e024ad054 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Pheochromocytoma
152 rdf:type schema:DefinedTerm
153 Na58ce306a8734e5ca692457efaa1f5f9 rdf:first sg:person.077074621.44
154 rdf:rest Nf1c99b1a7edc4c139690e95f2f558f80
155 Na97af9be5a994c458f8bd237ae4b5ffa schema:name dimensions_id
156 schema:value pub.1016994149
157 rdf:type schema:PropertyValue
158 Nabc814c9fada44f9929a5c52f5ab91e9 schema:issueNumber 11
159 rdf:type schema:PublicationIssue
160 Naf47c87082a34ffeb0a4d766581a60a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name 3-Iodobenzylguanidine
162 rdf:type schema:DefinedTerm
163 Nb2f072047f114f0fa67fcd28a469cdef schema:name doi
164 schema:value 10.1007/s002680010213
165 rdf:type schema:PropertyValue
166 Nb85dd8b023c64ead8ee2e0f120a8fd88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Thyroid Neoplasms
168 rdf:type schema:DefinedTerm
169 Nc65612329a3c4e9ab1737cfc20ca8633 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Female
171 rdf:type schema:DefinedTerm
172 Nce3bf2d8b8a34f3eaf7515508c4dc561 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Neuroendocrine Tumors
174 rdf:type schema:DefinedTerm
175 Ndea4ad495f724b2f8cf523db85ae0152 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Radionuclide Imaging
177 rdf:type schema:DefinedTerm
178 Neeba3d4d6a544d1096354956b1286373 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Radiopharmaceuticals
180 rdf:type schema:DefinedTerm
181 Nf1c99b1a7edc4c139690e95f2f558f80 rdf:first sg:person.0653324404.03
182 rdf:rest N86401cd8bb9848d2a166512d83036da1
183 Nfdc909059c214fd2af03ea0931393d5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Carcinoid Tumor
185 rdf:type schema:DefinedTerm
186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
187 schema:name Medical and Health Sciences
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
190 schema:name Oncology and Carcinogenesis
191 rdf:type schema:DefinedTerm
192 sg:journal.1086446 schema:issn 0364-2313
193 1432-2323
194 schema:name World Journal of Surgery
195 schema:publisher Springer Nature
196 rdf:type schema:Periodical
197 sg:person.01240530667.47 schema:affiliation grid-institutes:None
198 schema:familyName Rousseau
199 schema:givenName C.
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47
201 rdf:type schema:Person
202 sg:person.0623457423.87 schema:affiliation grid-institutes:None
203 schema:familyName Chatal
204 schema:givenName J.F.
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623457423.87
206 rdf:type schema:Person
207 sg:person.0653324404.03 schema:affiliation grid-institutes:None
208 schema:familyName Kraeber-Bodéré
209 schema:givenName F.
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03
211 rdf:type schema:Person
212 sg:person.077074621.44 schema:affiliation grid-institutes:None
213 schema:familyName Le Bodic
214 schema:givenName M.F.
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.077074621.44
216 rdf:type schema:Person
217 sg:person.0776514743.28 schema:affiliation grid-institutes:None
218 schema:familyName Resche
219 schema:givenName I.
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776514743.28
221 rdf:type schema:Person
222 sg:pub.10.1007/bf00199342 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003722545
223 https://doi.org/10.1007/bf00199342
224 rdf:type schema:CreativeWork
225 sg:pub.10.1007/s002590050268 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026262896
226 https://doi.org/10.1007/s002590050268
227 rdf:type schema:CreativeWork
228 grid-institutes:None schema:alternateName Service d'Anatomie Pathologique, C.H.U., Nantes-Saint Herblain, France, FR
229 Service de Médecine Nucléaire, Centre Régional de Lutte contre le Cancer René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR
230 schema:name Service d'Anatomie Pathologique, C.H.U., Nantes-Saint Herblain, France, FR
231 Service de Médecine Nucléaire, Centre Régional de Lutte contre le Cancer René Gauducheau, Boulevard Jacques Monod, 44805 Nantes-Saint Herblain Cedex, France, FR
232 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...